Alexion Pharmaceuticals a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company was founded in 1992 and is based in Cheshire, Connecticut.
ALXN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Alexion Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Alexion Pharmaceuticals Inc ranked in the 71th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 222% on a DCF basis. The most interesting components of our discounted cash flow analysis for Alexion Pharmaceuticals Inc ended up being:
As a business, ALXN is generating more cash flow than 87.01% of positive cash flow stocks in the Healthcare.
ALXN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 36.99% of tickers in our DCF set.
Alexion Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ALXN, try ABBV, FTLF, ARA, HUM, and SGRY.
Japan’s Ministry of Health, Labour and Welfare has approved Alexion Pharmaceuticals' (ALXN) Ultomiris (ravulizumab) for atypical hemolytic uremic syndrome (aHUS), for use in adults and children.Ultomiris is a long-acting C5 inhibitor for aHUS and is administered every other month for adults and children (20 kg or more) and monthly for children (<20 kg).Atypical HUS is an...
Alexion Pharmaceuticals (ALXN) announces that the Committee for Medicinal Products for Human Use ((CHMP)) has adopted a positive opinion, recommending marketing authorization in the European Union for a new 100 mg/mL intravenous ((IV)) advanced formulation of ULTOMIRIS (ravulizumab).ULTOMIRIS 100 mg/mL would constitute an advancement in the treatment experience by reducing...